Project Optimus aims to significantly change how early-phase oncology drug development and clinical trials are conducted, with this shift promising to enhance patient well-being by minimising side effects, improving treatment adherence and ensuring accurate drug dosing.
However, oncology drug developers face several challenges when implementing Project Optimus, including varying awareness and more complex clinical trial designs.
Our latest whitepaper explores Project Optimus in more detail, including:
- The reasons for refining dose optimisation in oncology drug development.
- The impact of Project Optimus on both patients and oncology drug developers.
- Challenges when implementing Project Optimus and solutions for overcoming them.
- How contract research organisations (CROs) can support developers implementing Project Optimus.